Instructions Asparkam solution for injection ampoule 10 ml blister No. 10
Composition
active ingredients: 1 ml of solution contains magnesium asparaginate anhydrous 40 mg (3.37 mg of magnesium), potassium asparaginate anhydrous – 45.2 mg (10.33 mg of potassium);
Excipients: sorbitol (E 420), water for injections.
Dosage form
Solution for injection.
Main physicochemical properties: transparent colorless or slightly yellowish liquid.
Pharmacotherapeutic group
Mineral substances. Magnesium preparations.
ATX code A12C C30.
Pharmacological properties
Pharmacodynamics
Asparkam has antiarrhythmic properties, replenishes the deficiency of magnesium and potassium ions. Magnesium activates sodium-potassium ATPase, as a result of which the intracellular sodium content decreases and the influx of potassium into the cell increases. When the sodium concentration in the cell decreases, sodium-calcium metabolism in vascular smooth muscles is inhibited, which leads to their relaxation, potassium ions stimulate the synthesis of ATP, glycogen, proteins, acetylcholine; potassium and magnesium support the polarization of cell membranes. Asparaginate promotes the influx of ions into the cell and participates in energy metabolism. The antiarrhythmic effect is realized due to the ability of the drug to eliminate electrolyte imbalance and reduce myocardial excitability and conductivity.
Pharmacokinetics
Not studied.
Indication
– For additional therapy in chronic heart diseases (heart failure, post-infarction period), in heart rhythm disorders, primarily ventricular arrhythmias;
– additional therapy in the treatment of digitalis drugs.
Contraindication
– Hypersensitivity to the components of the drug;
– acute and chronic renal failure;
– Addison's disease;
– third-degree atrioventricular block;
– cardiogenic shock (BP < 90 mm Hg).
Special safety measures.
With prolonged use of the drug, it is necessary to monitor the level of potassium and magnesium in the blood, as well as regular monitoring of electrolyte hemostasis indicators and ECG data.
Asparkam, as a drug containing potassium and magnesium, should be used with caution in patients with myasthenia gravis; in conditions that may lead to hyperkalemia, such as acute dehydration, widespread tissue damage, in particular severe burns. In this category of patients, it is recommended to regularly examine the level of electrolytes in the blood serum.
Since the drug contains sorbitol, patients with hereditary fructose intolerance should not use this drug.
Interaction with other medicinal products and other types of interactions
Concomitant use of the drug with potassium-sparing diuretics and/or ACE inhibitors increases the risk of developing hyperkalemia.
Use during pregnancy or breastfeeding
To date, no danger has been reported when using the drug in this category of patients.
Ability to influence reaction speed when driving or using other mechanisms
The drug does not affect driving.
Method of administration and doses
The drug is intended for intravenous administration only. Adults should be administered slowly intravenously by drip - 10-20 ml (the contents of the ampoule should be diluted in 50-100 ml of 5% glucose solution). If necessary, the dose can be repeated after 4-6 hours. The drug is suitable for combination therapy.
The course of treatment is determined by the doctor.
Children
There is insufficient experience with the drug in children, so it is not used in this age group of patients.
Overdose
Cases of overdose are unknown. In case of overdose, symptoms of hyperkalemia and hypermagnesemia may be observed.
Symptoms of hyperkalemia: general weakness, paresthesias, bradycardia, paralysis. Extremely high plasma potassium concentrations can lead to death from cardiac depression, arrhythmia, or cardiac arrest.
Symptoms of hypermagnesemia: nausea, vomiting, drowsiness, hypotension, bradycardia, weakness, slurred speech, double vision. At very high plasma concentrations of magnesium, hyporeflexia, muscle paralysis, respiratory arrest and cardiac arrest may develop.
In case of overdose, it is necessary to cancel K+ -, Mg 2 +-aspartate and it is recommended to carry out symptomatic treatment (calcium chloride 100 mg/min intravenously, dialysis, if necessary).
Adverse reactions
With rapid intravenous administration of the drug, the possibility of symptoms of hyperkalemia should be taken into account, such as nausea, vomiting, diarrhea, paresthesias and/or hypermagnesemia, such as facial flushing, hyporeflexia, convulsions, feeling of heat, respiratory depression.
Expiration date
2 years.
Storage conditions
Store in original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Packaging
5 ml in an ampoule, 10 ampoules in a box;
5 ml in an ampoule, 5 ampoules in a blister, 2 blisters in a pack;
10 ml in an ampoule, 5 ampoules in a blister, 2 blisters in a pack.
Vacation category
According to the recipe.
Producer
PJSC "Halychpharm".
Location of the manufacturer and its business address
Ukraine, 79024, Lviv, Opryshkivska St., 6/8.
